Research Topics
| Yixin WangSummaryAffiliation: Johnson and Johnson Pharmaceutical Research and Development Country: USA Publications
| Collaborators
|
Detail Information
Publications
Gene expression profiles and prognostic markers for primary breast cancerYixin Wang
Veridex LLC, Johnson and Johnson Company, San Diego, CA, USA
Methods Mol Biol 377:131-8. 2007....- Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancerYixin Wang
Veridex, LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
J Clin Oncol 22:1564-71. 2004..In this study, we used DNA chip technology to systematically identify new prognostic markers for tumor relapse in Dukes' B patients... - Gene expression-driven diagnostics and pharmacogenomics in cancerYixin Wang
Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
Curr Opin Mol Ther 7:246-50. 2005..Studies on gene expression profiling of clinically relevant tissue samples with the aim of finding gene markers to support disease prognosis and therapy decisions are reviewed... 
Copy number alterations that predict metastatic capability of human breast cancerYi Zhang
Veridex LLC, a Johnson and Johnson Company, San Diego, California, USA
Cancer Res 69:3795-801. 2009....
Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancerYuqiu Jiang
Veridex LLC, a Johnson and Johnson Company, 33 Technology Drive, Warren, NJ 07059, USA
J Mol Diagn 10:346-54. 2008..The ability to identify colon cancer patients with an unfavorable outcome may help patients at high risk for recurrence to seek more aggressive therapy...- Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemiaMitch Raponi
Veridex, L L C a Johnson and Johnson Company, San Diego, California 92121, USA
Clin Cancer Res 13:2254-60. 2007..Microarray technology was used to identify gene expression markers that predict response to the orally available farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in acute myelogenous leukemia (AML)... - A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of originDimitri Talantov
Veridex LLC, 33 Technology Dr, Warren, NJ 07059, USA
J Mol Diagn 8:320-9. 2006..Lastly, our assay demonstrated an accuracy of 76% when tested on an independent set of 48 metastatic samples, 37 of which were either a known primary or initially presented as carcinoma of unknown primary but were subsequently resolved... - Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservativeDondapati Chowdary
Veridex LLC, Johnson and Johnson Company, Warren, NJ, USA
J Mol Diagn 8:31-9. 2006..This novel finding demonstrates that prognostic signatures can be obtained from RNAlater preservative-suspended tissues, an important step in bringing gene expression signatures to the clinic... - Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancerJack X Yu
Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
BMC Cancer 7:182. 2007..Published prognostic gene signatures in breast cancer have few genes in common. Here we provide a rationale for this observation by studying the prognostic power and the underlying biological pathways of different gene signatures... - Novel genes associated with malignant melanoma but not benign melanocytic lesionsDmitri Talantov
Veridex, LLC, a Johnson and Johnson Company, San Diego, California 92121, USA
Clin Cancer Res 11:7234-42. 2005.... - A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemiaMitch Raponi
Veridex, 3210 Merryfield Row, La Jolla, CA 92121, USA
Blood 111:2589-96. 2008..Therefore, these data indicate that a 2-gene expression assay may have utility in categorizing a population of patients with AML who are more likely to respond to tipifarnib... - Identification and characterization of optimal gene expression markers for detection of breast cancer metastasisJohn Backus
Veridex, LLC, P O Box 4920, 33 Technology Drive, Warren, NJ 07059, USA
J Mol Diagn 7:327-36. 2005..An intraoperative molecular assay using these markers has the potential to significantly reduce second surgeries for patients undergoing SLN dissection... - Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lungMitch Raponi
Molecular Diagnostics, Veridex LLC a Johnson and Johnson Company, 3210 Merryfriend Row, San Diego, CA 92121, USA
Cancer Res 66:7466-72. 2006..0002; HR, 3.54; 95% CI, 1.74-7.19). This prognostic signature could be used to identify patients with early-stage high-risk NSCLC who might benefit from adjuvant therapy following surgery... - The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapyYi Zhang
Veridex LLC, Johnson and Johnson Company, San Diego, CA, USA
Breast Cancer Res Treat 116:303-9. 2009..To assess the benefit from adjuvant systemic tamoxifen therapy in breast cancer risk groups identified by the previously established prognostic 76-gene signature... - Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arraysMarina Bibikova
Genetic Analysis, Illumina, Inc, 9885 Towne Center Drive, San Diego, CA 92121, USA
Am J Pathol 165:1799-807. 2004..The DASL assay system should prove useful for high-throughput expression profiling of archived clinical samples... - Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancerYixin Wang
Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
Lancet 365:671-9. 2005..The ability to identify patients who have a favourable prognosis could, after independent confirmation, allow clinicians to avoid adjuvant systemic therapy or to choose less aggressive therapeutic options... - Gene-expression signatures in oncology diagnosticsAbhijit Mazumder
Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
Pharmacogenomics 7:1167-73. 2006..This article will examine some of these issues in greater detail, focusing on tissue type, platform comparison, biospecimen collection and signature validation... - Gene based prediction of clinically localized prostate cancer progression after radical prostatectomyDmitri Talantov
Veridex LLC, Raritan, New Jersey, USA
J Urol 184:1521-8. 2010..We combined an established nomogram and what to our knowledge are novel molecular predictors into a new prognostic model of prostate specific antigen recurrence... - Multicenter evaluation of an investigational prostate cancer methylation assayJonathan Baden
Veridex, LLC, Raritan, New Jersey, USA
J Urol 182:1186-93. 2009..0 ng/ml. We evaluated an investigational prostate cancer methylation specific polymerase chain reaction assay that detects aberrant methylation in 3 markers (GSTP1, RARbeta2 and APC) that indicate the presence of prostate cancer... - Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancerYuqiu Jiang
Veridex, LLC, a Johnson and Johnson Company, San Diego, CA, USA
Clin Chem 56:1492-5. 2010..There is a paucity of tumor-derived tissue available for molecular studies of CRPC patients. Circulating tumor cells (CTCs) in the blood of CRPC patients represent a possible avenue for interrogating the disease of such patients... - Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemiaMitch Raponi
Veridex, LLC, Johnson and Johnson Company, San Diego, CA 9212, USA
BMC Cancer 4:56. 2004..This study was conducted to identify genetic markers and pathways that are regulated by tipifarnib in acute myeloid leukemia (AML)... - Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluationGauri R Varadhachary
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
J Clin Oncol 26:4442-8. 2008..To evaluate the feasibility of a 10-gene reverse transcriptase polymerase chain reaction assay to identify the tissue of origin in patients with carcinoma of unknown primary (CUP) site... - Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expressionCarey K Anders
Duke University Medical Center, Box 3841, 3829 Duke South, Red Zone, Durham, NC 27710, USA
J Clin Oncol 26:3324-30. 2008..Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined... - The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicineJohn A Foekens
Department of Medical Oncology, Erasmus MC Daniel den Hoed, Josephine Nefkens Institute and Cancer Genomics Centre, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
Drug Discov Today 13:481-7. 2008..Here, we provide a short overview of the recent, promising developments in the field with emphasis on breast cancer... - Subtypes of breast cancer show preferential site of relapseMarcel Smid
Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
Cancer Res 68:3108-14. 2008..The five major molecular subtypes in breast cancer are evidently different with regard to their ability to metastasize to distant organ(s), and share biological features and pathways with their preferred distant metastatic site... - Validation and integration of gene-expression signatures in cancerAbhijit Mazumder
Expert Rev Mol Diagn 8:125-8. 2008 - Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation seriesChristine Desmedt
Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
Clin Cancer Res 13:3207-14. 2007..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment... - Lung metastasis genes couple breast tumor size and metastatic spreadAndy J Minn
Department of Radiation and Cellular Oncology, Center for Molecular Oncology, and Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL 60637, USA
Proc Natl Acad Sci U S A 104:6740-5. 2007.... - Genes associated with breast cancer metastatic to boneMarcel Smid
Department of Medical Oncology, Erasmus MC-Daniel den Hoed, Rotterdam, The Netherlands
J Clin Oncol 24:2261-7. 2006.... - Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancerJohn A Foekens
Department of Medical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
J Clin Oncol 24:1665-71. 2006..The aim of this study was to validate this gene signature in an independent more diverse population of LNN patients from multiple institutions... - A smooth response surface algorithm for constructing a gene regulatory networkHongquan Xu
Department of Discovery Research Informatics, Bioinformatics, Pfizer Global Research and Development, Ann Arbor 48105, USA
Physiol Genomics 11:11-20. 2002.... - Age-specific differences in oncogenic pathway deregulation seen in human breast tumorsCarey K Anders
Division of Medical Oncology, Department of Medicine, Duke University, Durham, North Carolina, USA
PLoS ONE 3:e1373. 2008..To define the biology driving the aggressive nature of breast cancer arising in young women...